J.P. Morgan says the gold market will see a shift in its price target.

The average one-year price target for Protalix BioTherapeutics (NYSEAM:PLX) has been revised to $11.22 / share. This is a decrease of 12.00% from the prior estimate of $12.75 dated January 11, 2026. The price target is an average of many targets provided by analysts.

Morgan Stanley cuts target 30% to $213 on AI funding fears while Guggenheim holds $400 target. Wall Street divided on cloud bet.

Not only has Morgan Stanley downgraded Hindustan Aeronautics, but also cut its share price target by 34%. The revised price target implies a potential downside of 20% from current levels.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target ...

Shares of the chip maker Advanced Micro Devices dropped double-digits in Wednesday afternoon trading after the company’s earnings report fell short of Wall Street’s sky-high expectations. AMD shares were down 17% on Wednesday,